1. High incidence of post‐transplant cytomegalovirus reactivations in myeloma patients undergoing autologous stem cell transplantation after treatment with bortezomib‐based regimens: a survey from the Rome Transplant Network. Issue 1 (12th November 2013) Authors: Marchesi, F.; Mengarelli, A.; Giannotti, F.; Tendas, A.; Anaclerico, B.; Porrini, R.; Picardi, A.; Cerchiara, E.; Dentamaro, T.; Chierichini, A.; Romeo, A.; Cudillo, L.; Montefusco, E.; Tirindelli, M.C.; De, P.; Annino, L.; Petti, M.C.; Monarca, B.; Arcese, W.; Avvisati, G. Journal: Transplant infectious disease Issue: Volume 16:Issue 1(2014) Page Start: 158 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Prospective surveillance vs clinically driven approach for CMV reactivation after autologous stem cell transplant. Issue 2 (February 2016) Authors: Mengarelli, A.; Annibali, O.; Pimpinelli, F.; Riva, E.; Gumenyuk, S.; Renzi, D.; Cerchiara, E.; Piccioni, L.; Palombi, F.; Pisani, F.; Romano, A.; Spadea, A.; Papa, E.; Cordone, I.; Canfora, M.; Arcese, W.; Ensoli, F.; Marchesi, F. Journal: Journal of infection Issue: Volume 72:Issue 2(2016) Page Start: 265 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗